Paper Details

  1. Home
  2. Paper Details

Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol.

Author: BeasleyR, BremnerP, BurgessC, CraneJ, SiebersR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fenoterol was found to be a more potent beta-agonist than albuterol, resulting in greater maximum cardiac and metabolic effects. Albuterol, however, is associated with a lower risk of death.
Paper Details　
Original Abstract of the Article :
STUDY OBJECTIVE: To compare the maximal extrapulmonary effects of the beta-agonists albuterol and fenoterol in eight healthy volunteers. SUBJECTS AND METHODS: In this double-blind study, we have examined the maximum cardiac effects (electromechanical systole [QS2I]--a measure of inotropy, heart rat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1378/chest.109.4.957

データ提供：米国国立医学図書館（NLM）

Partial vs full beta-receptor agonism: Unraveling the Mystery of Asthma Medications

The world of asthma medication is a vast desert, with many different treatments for this chronic respiratory condition. This research delves into the exciting world of beta-agonists, specifically focusing on two prominent players: albuterol and fenoterol. The study employs a double-blind approach, a technique akin to a camel caravan navigating through a sandstorm, to evaluate the maximal cardiac and metabolic effects of these drugs in healthy volunteers.

Albuterol's Partial Agonism: A New Perspective

The results of this study reveal that albuterol, when compared to fenoterol, acts as a partial agonist at beta-receptors. This means that albuterol doesn't activate the receptors as fully as fenoterol, resulting in a more controlled effect. Imagine a camel caravan venturing into a sandstorm; albuterol is like a seasoned guide using a steady pace, while fenoterol is like a spirited camel rushing headlong into the storm.

Healthier Choices for Asthma Management

The researchers concluded that albuterol, when inhaled in doses recommended for severe asthma, produces lesser maximum cardiac and metabolic effects than fenoterol. This suggests that albuterol may be a safer option for patients with asthma, especially those at risk for cardiac complications. Think of it like choosing a sturdy camel for a long journey versus a faster but less reliable steed. Ultimately, finding the right medication is like navigating a desert, requiring careful consideration of individual needs and potential risks.

Dr.Camel's Conclusion

This research shines a light on the subtle differences between two commonly used asthma medications. While both are effective in opening airways, albuterol's partial agonist property may translate into a safer profile for certain patients. As researchers continue to explore the vast desert of asthma treatment options, we gain a deeper understanding of how to manage this debilitating condition.

Date :
  1. Date Completed 1996-07-11
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

8635377

DOI: Digital Object Identifier

10.1378/chest.109.4.957

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.